249 results on '"Glicksman, Rachel"'
Search Results
2. Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials
3. The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial
4. TOward a comPrehensive supportive Care intervention for Older men with metastatic Prostate cancer (TOPCOP3): A pilot randomized controlled trial and process evaluation
5. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office
6. Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis
7. Late Toxicities of Prostate Radiotherapy: Can We Further SMARTen Up the Therapeutic Index?
8. Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer
9. Enhancing International Cancer Organization Collaborations: King Hussein Cancer Center and Princess Margaret Cancer Centre Model for Collaboration
10. Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors
11. Early-Stage Breast Cancer: A Critical Review of Current and Emerging Practice.
12. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond
13. MRL Prostate GTV Focal Boost: Is Prep Relevant?
14. GTV Boost for Prostate Cancer: Early Comparison of Patient-Reported QoL with MR-Linac vs HDR Brachytherapy
15. Moving Unfavorable Small-Bowel Anatomy Away From the Prostate to Optimize Radiation Therapy Plans With the GU-Lok
16. Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials
17. Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial
18. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis
19. Mammographic Surveillance in Older Women With Breast Cancer in Canada and the United States: Are We Choosing Wisely?
20. Primary retroperitoneal lymph node dissection for metastatic non‐seminomatous germ cell tumours: outcomes and adjuvant chemotherapy.
21. The Capital Investment Strategy for Radiation therapy in Ontario: A Framework to Ensure Access to Radiation Therapy
22. Prospective evaluation of patient-reported anxiety and experiences with adaptive radiation therapy on an MR-linac
23. FASTRACKing Our Understanding of Renal Function After Kidney Stereotactic Ablative Body Radiation Therapy.
24. Elective pelvic nodal irradiation in elderly men treated with hypofractionated radiotherapy
25. Improving Quality of Radiation Therapy Care Across Ontario using a Community-of-Practice Approach
26. Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer
27. Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT).
28. Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer
29. Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT)
30. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office
31. 2108: Initial clinical experience with GTV boost for prostate cancer using MR-Linac
32. 1478: The role of SBRT in oligoprogressive malignant disease, a phase 2 prospective trial (NCT04122469)
33. 53: Patient-reported outcomes and experience measures with online adaptive radiotherapy on MR-Linac
34. 48 Focal Brachytherapy for Localized Prostate Cancer: Systematic Review and Meta-Analysis
35. 149 Accumulated Kidney Dose in Renal Stereotactic Body Radiotherapy: Analysis from a Prospective Phase II Trial
36. Practice-based training strategy for therapist-driven prostate MR-Linac adaptive radiotherapy
37. The predictive value of nadir neutrophil count during treatment of cervical cancer: Interactions with tumor hypoxia and interstitial fluid pressure (IFP)
38. Oligometastasis in Prostate Cancer: Can We Learn from Those “Excluded” from a Phase 2 Trial?
39. Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy
40. Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice
41. MP33-02 PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION FOR METASTATIC NONSEMINOMATOUS GERM CELL TUMOR: REVIEW OF ONCOLOGIC OUTCOMES AND THE ROLE OF ADJUVANT CHEMOTHERAPY
42. Qualitative Patient Experiences with a Person-Centered vs. Standard Model of Care for Breast Radiation Therapy (PERSON Study)
43. Figure S5 from Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
44. Supplementary Legends from Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
45. Supplementary Table S1 from Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
46. European Association of Urology (EAU) Testicular Cancer Guidelines Panel: A new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance.
47. Prospective Evaluation of Patient-Reported Anxiety and Experienceswith Adaptive Radiation Therapy on an Mr-Linac
48. Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer
49. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer
50. Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.